Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Steven Bulwa is an investment analyst with a focus on new developments in science, technology and medicine and the companies poised to benefit. He has contributed to TheStreet.com, Realmoney.com and SeekingAlpha.com, BusinessInsider.com, Mediaite.com and HuffingtonPost.com among others. Steven has actively followed developments in technology for over 20 years, working with a scientific advisory board to validate potential investments. Early in his career, as a musician and recording engineer, Steven recognized the importance of the shift from analog to digital recording. This inspired his first stock investment in a company providing hardware and software solutions to television news providers converting to a digital video environment. The success of this investment inspired Steven to continue to delve into yet-to-be recognized investment opportunities in technology. While writing for thestreet.com in 2006, Steven was one of the first analysts to identify the explosive investment opportunity of 3D Printing. At the time he wrote articles about Stratasys(SSYS) and 3D Systems(DDD). Steven's picks like Nuvasive(NUVA) were also featured on Jim Cramer's Mad Money on CNBC. He has also acted as a consultant to companies looking to acquire new technologies including nanotechnology.
A practical investor, Steven also called the demise of the housing and mortgage markets after listening to one of Ben Bernanke’s early testimonies while simultaneously learning of Bank of America’s efforts to proactively renegotiate troubled home loans. In our capitalist economy, companies only renegotiate out of desperation, trouble was obviously coming!
Technology now evolves so rapidly that there are always great new technology companies with tremendous growth potential to invest in. Big cap tech's strongest growth is past, Steve wants to help you invest in tomorrow’s Apple,Google, or Microsoft.
Physician Assistant trained at State University of New York at Stony Brook. I am an Allied Fellow Member of the American Urological Association, Fellow of the American Academy of Physician Assistants, Fellow of the Urological Association of Physician Assistants, and former Vice President of the Adirondack Society of Physician Assistants (a Continuing Medical Education program). I am credentialed by the National Commission on the Certification of Physician Assistants (NCCPA)
My career is exclusively focused in surgery (urologic and general surgery) for the past 12 years, working with patients who receive chemotherapy, surgery, radiation, and active surveillance. My small rural practice (1 Physician, 1 Physician Assistant) is now an infusion center for Provenge. Small community practices are at the greatest risk of financial loss during Provenge treatment. My investment strategy with Provenge is closely guarded with a healthy amount of skepticism. I see the reality of the acceptability of Provenge, and other high-priced chemotherapies that have come to market in 2010-2011.
My practice does not perform prostate cancer surgery, chemotherapy, or radiation therapy. Therefore, as a general urology practitioner, I remain largely unbiased and I have served as a clinical opinion in many articles about DNDN and Provenge on seekingalpha.com, and continue to educate my patients and community physicians about Provenge as a treatment option.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Timeless Wealth is a leading Publisher of Investment-Opinion content supported by research. We utilize a mix of fundamental and behavioral analysis to uncover undervalued investment opportunities in the small cap sector.
Follow us on twitter: https://twitter.com/#!/TimelessWealth
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
Michael Shulman is currently editor of investment advisory services and is the author of Made in America, Otterbourn Publishing, May, 2013 and of Sell Short (John Wiley & Sons, 2009).
Options Income Blueprint is a unique advisory service published by Traders Reserve and based on fundamental analysis with recommendations for option selling strategies and positions to generate consistent monthly income.
Made in America: Inside Stories of Success is built around four factories -- Trek Bicycles, Red Wing Shoes, the GM Flint Michigan pickup truck assembly plant and Airstream. The book pushes aside the myth of the decline in the US manufacturing - the US is still the world's largest manufacturing nation - through the success of these four factories and companies.
Mr. Shulman joined the Traders Reserve after ten years with InvestorPlace Media, his turn to financial advisory services coming after more than twenty years actively involved in the development of new technologies. He was founder and CEO of an internet company, AtYourBusiness.com, sat on the board of The NextGen I venture fund, worked as a consultant or founding employee of several technology startups, was a product manager for a Silicon Valley Start up when the country had 49 personal computer companies and did similar work in the mid-1980s for AT&T.
Mr. Shulman graduated Georgetown University with a degree in philosophy in 1977, worked in the renewable energy field for five years – same vocabulary, hope and promises as we are hearing today - before moving to the marketing of industrial and agricultural products with several New York firms. When asked if there is a thread in his career his answer is “Yes. Change, what is new. And what other people are missing, things they think are not normal - things I see as becoming a standard or success."
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.